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Summary JM216 (bis-acetato ammine dichloro cyclohexylamine Pt IV) is an oral platinum complex presently
undergoing phase II clinical trials. Previous studies have identified some of its biotransformation products in
clinical materials. This study evaluated the nature of JM216 biotransformation products intracellularly in two
different human ovarian carcinoma cell lines, one relatively sensitive to platinum agents (CH1: JM216 4 h IC50
of 5.8 gM) and the other relatively resistant (SKOV3: JM216 4 h IC50 of 60.7 gM). Metabolic profiles were also
evaluated at different growth status and in cells pretreated with buthionine sulphoximine (BSO), an agent
known to decrease intracellular glutathione levels. Results showed that JM216 enters the cells and that the
nature and percentage of biotransformation products was dependent upon glutathione levels. Furthermore,
results support the view that the previously reported peak A biotransformation product contains a glutathione
adduct. In exponentially growing SKOV3 cells which contain higher glutathione levels than CHI, (82.5 vs
37.8 nmol mg-' protein), peak A represented 89% of total platinum 4 h after JM216 exposure compared with
only 24% in CHI. Moreover, 60-70% depletion of glutathione achieved by 24 h pretreatment of cells with
BSO resulted in a significant decrease in peak A in both cell lines and increased the cytotoxicity of JM216 in
both CHI and SKOV3 by approximately 2-fold. Following a 4 h exposure of exponentially growing SKOV3
cells to JM216, only peak A (89%) and JM216 (11%) could be detected whereas in CHI cells, peak A (24%),
JM216 (73%) and JM118 [cis-ammine dichloro (cyclohexylamine) platinum II] (3%) were detected. However,
in CH1 cells at confluence, where glutathione is lower (8 nmol mg-' protein) four metabolites (plus JM216
itself) were detected following exposure to 50 tM JM216; peak A, JM118, JM383 (bis-acetato ammine
(cyclohexylamine) dihydroxy platinum IV) and an unidentified metabolite (D), also observed in patient's
plasma ultrafiltrate. In confluent SKOV3 cells exposed to 50 pM JM216, peak A, JM216 and JM118 were
detected. A further unidentified metabolite observed in patients receiving JM216 (metabolite F) was not formed
inside these tumour cells. Overall, these data suggest that glutathione conjugation represents a major
deactivation pathway for JM216.
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JM216 is a platinum IV ammine/amine dicarboxylate that
has shown high in vitro activity in a panel of human ovarian
carcinoma (Kelland et al., 1992), lung cancer (Twentyman et
al., 1992), human cervical squamous cells (Mellish et al.,
1993) and murine leukaemia cell lines (Orr et al., 1994). This
activity was translated in vivo in a panel of human ovarian
xenograft models (Kelland et al., 1993). JM216 showed no
preclinical renal toxicity and no peripheral neuropathy
(McKeage et al., 1993, 1994a). Activity was also observed
by the oral route (Giandomenico et al., 1991; Kelland et al.,
1993) and, as a result, JM216 is the first orally administrable
platinum complex to have entered clinical trial. It is presently
undergoing phase II clinical trial in small-cell lung cancer,
non-small-cell lung cancer and ovarian carcinoma. In the
phase I trial, it was established that the dose-limiting toxicity
is myelosuppression and the drug is well tolerated with
prophylactic antiemetics (McKeage et al., 1995). Preclinical
studies have shown that multiple administrations give the
best anti-tumour responses (McKeage et al., 1994b) and this
has been verified in patients, where multiple administrations
could overcome the saturability in absorption observed in the
single-dose study (McKeage et al., 1994c; Raynaud et al.,
1995). It has been shown that JM216 is converted in patients'
plasma into at least six different biotransformation complexes
and that these biotransformation products are active in vitro
and in vivo (Poon et al., 1995; Raynaud et al., 1996). Three of
the metabolites present in patients have not yet been
identified.
Resistance to platinum agents is often multifactorial and
has been described as the consequence of a cellular uptake
deficiency, increased DNA repair or enhanced cellular
detoxification (Richon et al., 1987; Andrews et al., 1988;
Andrews and Howell, 1990; Hosking et al., 1990). Our own
previous studies have shown that in the acquired cisplatin-
resistant human ovarian carcinoma cell line, 4lMcisR,
reduced drug accumulation is the major mechanism of
resistance to cisplatin. However, some platinum IV am-
mine/amine complexes such as JM216 show non-cross-
resistance in 4lMcisR cells and accumulate as much as in
the parent line (Loh et al., 1992; Sharp et al., 1995).
Glutathione or methionine conjugation is a common
inactivation pathway for various nucleophiles. Glutathione
has been shown to be overexpressed in numerous cell lines
resistant to platinum agents and its depletion by buthionine
sulphoximine (BSO) increases the cytotoxicity of platinum
agents (Andrews et al., 1985; Mistry et al., 1991). It has been
demonstrated that intracellular glutathione correlates with
the cytotoxicity of numerous platinum agents and more
particularly Pt IV complexes (Lewis et al., 1988; Hosking et
al., 1990; Mistry et al., 1991, 1993; Meijer et al., 1992). The
intracellular formation of glutathione conjugates with
platinum drugs has been demonstrated with cisplatin,
tetraplatin and oxaliplatin (Mistry et al., 1993; Pendyala et
al., 1995). In our metabolic studies in patients and mice
plasma, a very early eluting metabolite (unidentified by mass
spectroscopy) co-eluted with glutathione adducts of JM216
generated in vitro (unpublished data). It has therefore been
assumed that this peak was a glutathione adduct.
The aim of this study was to characterise JM216
intracellular metabolism and to evaluate the role of
glutathione in drug detoxification. Therefore, JM216
cytotoxicity and metabolism profiles were determined in
two cell lines; one sensitive to platinum complexes (CH1) and
one resistant to platinum complexes (SKOV3) and known to
have relatively high levels of glutathione (Mistry et al., 1991).
No difference in uptake of JM216 has been observed between
these two cell lines (CF O'Neill et al., unpublished data). The
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effects of buthionine sulphoximine (BSO) on the cytotoxicity
and metabolic profiles are presented. The effect of growth
status on the different biotransformation profiles was also
evaluated.
Materials and methods
Chemicals
Glutathione, buthionine sulphoximine (BSO) and nitroben-
zoic acid, were obtained from Sigma Chemicals UK Ltd.
Phosphate-buffered saline (PBS) was obtained from Culture
Kitchen, London, UK; JM216 was obtained from the
Johnson Matthey Technology Centre.
sulphorhodamine B assay as described previously (Kelland et
al., 1992). IC50 values were determined graphically.
Glutathione measurements
Cells were extracted with 0.6% sulphosalicyclic acid at 4°C
and glutathione measured with a glutathione assay previously
described (Griffiths et al., 1980) and expressed vs protein
content (Lowry et al., 1951).
Statistics
Results are presented as means+standard errors. The
differences between groups are evaluated with t-tests for
unpaired samples (Inplot software).
Cell lines
The human ovarian carcinoma cell lines used in this study
were SKOV3 and CHI as described previously (Hills et al.,
1989). Cells were grown in Dulbecco's modified Eagle
medium (DMEM) plus 10% fetal calf serum (FCS),
50 jMg ml-' gentamicin, 2 mM glutamine and 0.5 ig ml-'
hydrocortisone at 37°C in a 10% carbon dioxide atmo-
sphere. Cells were periodically checked and found to be free
of mycoplasma and used in this study from passage 25 to 50.
Cells were seeded in T175 flasks (106 cells per flask) and were
allowed to attach for 24 h before drug exposure for
exponentially growing cells and for 5 days for confluent cells.
Metabolic profiles
Following attachment the cells were exposed to medium
containing 12.5 jiM BSO for CHI cells and 50 gM BSO for
SKOV3 cells for 24 h (37°C, 10% carbon dioxide atmo-
sphere). These doses were chosen because they have
previously been shown to decrease GSH levels by over 80%
in these cell lines (Mistry et al., 1991). Control cells were
exposed to medium only. JM216 (50 gM) was added to the
control flasks and the BSO-treated cells and left for 1, 2 or
4 h (37°C, 10% carbon dioxide atmosphere). The medium
was then removed and cells were washed twice with PBS.
After the medium was removed, the cells were washed three
times with ice-cold PBS and then scraped and harvested in
2 x 0.5 ml PBS. The suspension was then sonicated (polytron
sonicator MSE Fisons Ltd) for 2 x 15 s at 14 mAmps. An
aliquot of the cell sonicate was taken for protein analysis; the
remainder was ultrafiltered using Amicon 10 000 MW
exclusion membranes (4800 r.p.m. 45 min at 40C) and stored
in liquid nitrogen until analysis.
JM216 metabolites were separated by high performance
liquid chromatography (HPLC) on a polymeric phase column
(PLRP-S). Samples (200 Ml) were injected and eluted with a
water/acetonitrile linear gradient (15-95% acetonitrile over
30 min). Fractions (0.2 min) were collected and platinum was
evaluted in those fractions by atomic absorption spectro-
photometry as described elsewhere (Raynaud et al., 1995).
The identity of the metabolites was determined by co-elution
with authentic standards. Structures of the various known
JM216 metabolites are shown in Figure 1.
Results
The intracellular biotransformation of JM216 in CHI cells
after treatment with JM216 with or without BSO pretreat-
ment is shown in Figure 2 (and in Figure 4 for SKOV3). In
both cell lines and under all conditions, some JM216
(fraction 99-106) could be detected intracellularly (Table
I). In exponentially growing CHI (Figure 2), it represented
73% of ultrafiltrable platinum 4 h after treatment. Traces of
JM118 (fraction 82-90) could also be measured and an early
eluting peak (A, fraction 21-36) was also seen. This peak A
co-eluted with the metabolite formed when incubating JM118
with glutathione (Figure 3).
In SKOV3 exponentially growing cells (Figure 4), no
JM118 could be detected and A represented 89% of total
ultrafiltrable platinum 4 h after treatment vs only 24% in
CHI (Figure 2). Treatment of both cells with BSO for 24 h
significantly decreased peak A from 24% to 15% in the CHI
and from 89% to 70% in the SKOV3 (P<0.001) (4 h JM216
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Cytotoxicity assay
Cytotoxicity assays were performed in 96-well microtitre
plates after trypsinisation with 0.02% EDTA/0.05% trypsin.
Cells were plated (5000 per well for CHI and 3000-4000 per
well for SKOV3). Cells were then left to attach for 24 h. In
the BSO-treated cells, the cells were exposed to BSO for 24 h
after attachment and before JM216 exposure while other cells
were only given medium. The medium was then removed and
replaced with increasing concentrations of JM216-containing
medium for 2 h or 4 h (at 37°C, 10% carbon dioxide
atmosphere). The JM216-containing medium was aspirated
and replaced with fresh medium and the cells were left to
grow for a further 96 h. Cytotoxicity was evaluated using the
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Figure 1 Structures of JM216 biotransformation products.
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Figure 2 Metabolic profile in exponentially growing CHI 1 h (a) and 4h (b) after treatment with 50 gM JM216 and in the same
conditions (c) and (d) following 24h pretreatment with 12.5uM BSO.
Table I Intracellular platinum levels (ngmg7l protein) following
cell exposure to 50OM JM216
(a) Cell lines growing exponentially
Cell line and Time (h) Peak A JM118 JM216
SKOV-3 1 21.9 ND 17.6
SKOV3 + BSO 1 9.9 ND 41.3
SKOV-3 4 88.4 ND 10.9
SKOV3 + BSO 4 22.8 ND 10.0
CHI 1 45 8.0 61.7
CHI + BSO 1 20.3 18.3 82
CHI 4 20.4 2.1 62.1
CHI + BSO 4 20.6 8.1 106.7
(b) Cell lines exposed when confluent
Cell line and
time (h) Peak A JM383 Peak D JMJ18 JM216
SKOV3 1 60.5 ND ND 16.2 86.5
SKOV3 4 97 ND ND 7.0 63.0
CHI 1 17.7 2.1 5.2 14.4 16.0
CHI 4 97.6 3.5 3.9 10.5 20.2
ND, not detectable. Values represent the mean of2 -3 experiments.
exposure) and increased the JM216 peak at both 1 h and 4 h
after treatment (e.g. at 1 h 54-68% in CHI and 44-80% in
SKOV3; at 4 h 73 -79% in CHI and 11 -30% in SKOV3)
(Table I).
In CH1 and SKOV3 cells exposed to JM216 when
confluent, the intracellular metabolic profile differed from
that observed in exponentially growing cells (Figure 5). In
CH1, five platinum-containing peaks could be identified (A,
JM383, D, JM1 18 and JM216). D co-eluted with metabolite
D observed in patients' plasma ultrafiltrates (Raynaud et al.,
1995). In SKOV3, only three platinum peaks could be
measured at confluence (A, JM118 which could not be
detected in exponentially growing cells and JM216).
Significantly higher levels of JM118 were observed in both
lines at confluence compared with exponentially growing cells
(Table I).
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Figure 3 Metabolic profile following incubation of 50gM JM118
with glutathione during 24h in saline.
Glutathione levels in the different lines under the various
conditions are shown in Table II. Glutathione levels were 2.2-
fold higher in exponentially growing SKOV3 compared with
CHI (P<0.001) and were decreased by over 60% following
treatment with BSO (Table II). In confluent cultures, the fold
difference in glutathione levels was 5.7-fold. In CHI cells, the
levels of glutathione 4 h after JM216 treatment were slightly
decreased (but the difference was not quite significant
P=0.12). In SKOV3 cells, 4 h after JM216 treatment,
glutathione levels were significantly lower than in control
SKOV3 cells (P<0.001).
The cytotoxicity of JM216 following 2 h or 4 h exposure
and of cisplatin following 2 h exposure is shown in Table III.
JM216 and cisplatin were both significantly more potent in
the CHI line compared with the SKOV3 (P<0.001).
Following 2 h drug exposure in the SKOV3 cells, the
cytotoxicity of both drugs was increased by approximately
2-fold by the BSO pretreatment, while in the CHI cell line
only JM216 cytotoxicity was affected by BSO (again by
approximately 2-fold). Following 4 h exposure to JM216, the
cytotoxicity data were not significantly different from that
following 2 h exposure (Table III).
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inactivation (Andrews & Howell, 1990; Eastman 1987a,b;
Masuda et al., 1988; Loh., 1992). Glutathione, the
predominant intracellular non-protein thiol, provides a
major defence against electrophiles. Increased glutathione
levels are a common feature in cellular resistance against
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Figure 4 Metabolic profiles in exponentially growing SKOV-3 1 h (a) and 4h (b) after treatment with 50gM JM216 and pretreated
with 50pM BSO before drug treatment (c) and (d).
118 216
A D
o 20 40 60 80
Fraction number
0
0.'
0)
0)
o
0)
C
E
Co
0-
100 120
216
118
A
C
._
0 0. a
0)
E
0) a)
C
E
C
C+o
0-
A
216
118
20 40 60 80 100
Fraction number
A
216
118
0 0 20 40 60 80 100
Fraction number
120
Figure 5 Metabolic profiles in CHI treated at confluence with 50gM JM216 Ih and 4 h after treatment (a) and (b) and SKOV-3 (c)
and (d).
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Table II Glutathione levels (nmolmg- protein) in CHI and
SKOV-3 cells
(a) At differing growth status
Growth status/treatment CHJ SKOV3
Exponential 37.8+ 1.2 82.5+3.5
Exponential + BSO 14.4+3 22+6
Confluent 8+0.6 46+5.8
(b) Following JM216 (50gM) exposure; exponentially growing cells
Cells CHI SKOV3
Control 33.3 + 1.1 68.3+1.5
JM216 2h 32.9+ 1.4 65.8+0.77
JM216 4h 26.7+2.7 55.0+ 1.5
Values represent the mean +s.e.
Table HII Cytotoxicity (IC50 in gM) following exposure of cell lines
to JM216 for 2 or 4h or cisplatin for 2h+ BSO 24h pretreatment
(12.5,M CHI; 50pM SKOV3)
Treatment/cells CHI SKOV3
JM216 2h 6.7+1.1 77+ 18
JM216+ BSO 2h 3.1+0.5 (2.2) 36±5.2 (2.1)
JM216 4h 5.8+1.0 60.7+ 5.7
JM216 + BSO 4h 3.0+0.5 (1.9) 23.7+4.9 (2.6)
Cisplatin 2h 2.8+0.7 80+6.1
Cisplatin + BSO 2h 2.3+0.4 (1.2) 51+9.8 (1.6)
Values represent the mean+s.e. Figure in brackets give the dose
modification factor owing to pretreatment with BSO.
platinum drugs including JM216 (Mellish and Kelland, 1994)
and levels of glutathione have been shown to correlate with
sensitivity to platinum agents in human and murine tumour
cells (Hosking et al., 1990; Mistry et al., 1991; Meijer et al.,
1992). Depletion ofglutathione with BSO has previously been
shown to correlate with sensitivity to platinum drugs,
particularly platinum (IV) complexes (Mistry et al., 1991,
1993; Meijer et al., 1992; Pendyala et al., 1995). This work
supports the view that glutathione conjugation is an
important inactivation pathway for JM216. Furthermore, it
shows that in our experimental conditions, JM216 enters the
cells and its converted to a variety of metabolites (A, JM383,
D and JM118).
Our results also support the notion that peak A includes a
glutathione adduct. Hence the percentage of A decreases
when the cells are treated with BSO and is higher in cells
(SKOV3) with higher glutathione concentrations. Further-
more, the glutathione levels decrease in both cell lines
following JM216 treatment. Levels of glutathione can
influence both the nature of the metabolic profile and,
consequently, the cytotoxicity of JM216. In our experimental
conditions, cell density clearly affected both the glutathione
content and the metabolic profiles. Previous studies have
demonstrated that growth status affects the cellular levels of
glutathione (Batist et al., 1986; Post et al., 1983). In
exponentially growing cells, only the parent drug, the
glutathione adduct and, for CHI, traces of JM118, could
be detected in cell ultrafiltrates, while five metabolites could
be detected in confluent cells including significant levels of
JM118. This could be a consequence of a higher trapping of
these metabolites by glutathione in exponentially growing
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cells or could also be caused by the effect of glutathione on
DNA repair. Indeed, glutathione has been shown to facilitate
DNA repair in cell lines with acquired resistance to cisplatin,
but the mechanism is still poorly understood (Ali-Osman and
Rairkar, 1992; Rairkar and Ali-Osman; 1992). In our
experimental conditions BSO pretreatment increased the
intracellular free platinum levels in the resistant SKOV3
cells. As little difference in JM216 intracellular uptake has
been observed at an equimolar dose of 50 gM (CF O'Neill,
personal communication), and no difference in overall DNA
platination at equimolar doses is seen (Mellish et al., 1995),
our data suggest that other forms of interactions (proteins)
might be relevant in these cells. Previous studies have
demonstrated that, in certain cell lines, glutathione con-
jugates may be excreted by an energy-dependent pump which
is overexpressed in at least some cells resistant to platinum
agents (Ishikawa et al., 1993, 1994). Further studies suggest
that this pump may be related to the MRP-associated protein
(Muller et al., 1994; Versanvoort et al., 1995). However, we
have not been able to detect MRP in SKOV3 cells (SY
Sharp, personal communication).
The intracellular profiles observed following JM216
administration show the formation of a variety of
metabolites (A, JM383, D and JM118) and indicate that
JM216 enters the cells. Another platinum (IV) complex,
tetraplatin, tetrachloro (D,L, -trans)1,2 diaminocyclohexane-
platinum (IV) (ormaplatin), was shown to be reduced very
rapidly in tissue culture medium to dichloro(D,L-trans)1,2-
diaminocyclohexaneplatinum (II) (Gibbons et al., 1989),
while iproplatin [cis-dichloro-trans-dihydroxy-bis-isopropyla-
mine platinum(IV)] was reduced intracellularly to cis-
dichloro-bis-isopropylamine platinum (II) (Pendyala et al.,
1989). In our experimental conditions, it is not clear whether
the reduction of JM216 occurs intracellularly or extracellu-
larly.
Our results show that some metabolites previously
observed in patients' plasma ultrafiltrates can be observed
intracellularly; those being A, JM383, D and JM118
(Raynaud et al., 1995, 1996). However, JM216 itself was
never detected in patients' plasma ultrafiltrates and a late
eluting metabolite F was not seen intracellularly and no
JM559 could be measured.
The fact that JM216 was active in mice bearing human
ovarian xenografts, where it also becomes biotransformed
(unpublished results), suggests that cytotoxic species enter the
cells. We have also previously shown that JM216 metabolites
show significant cytotoxicity (Raynaud et al., 1996). Our
results might indicate that the cytotoxicity observed following
treatment with JM216 is the result of the interaction of a
variety of species with the DNA; it has recently been
demonstrated that Pt (IV) complexes such as oxoplatin may
generate DNA adducts directly (Novakova et al., 1995).
In conclusion, this work shows that glutathione levels
drive intracellular JM216 metabolism. When glutathione
levels are low, more biotransformation products are formed
inducing higher cytotoxicity. Trapping by glutathione reduces
both the number and the relative amount of parent, and
cytotoxic metabolites, thereby decreasing cytotoxicity.
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